Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 

 Headlines:

 

Category: Cardiology | Family Medicine | Internal Medicine | Pulmonology | Journal

Back to Journal Articles

Pulmonary Hypertension May Be Reversible With Viagra

Last Updated: August 05, 2009.

 

Study finds drug can reduce stiffness of arteries and restore sensitivity to vasodilators

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
Patients with pulmonary hypertension and heart failure have stiffer arteries and reduced sensitivity to vasodilators compared with patients without hypertension, which can be reversed by sildenafil (Viagra), according to a study in the Aug. 11 issue of the Journal of the American College of Cardiology.

WEDNESDAY, Aug. 5 (HealthDay News) -- Patients with pulmonary hypertension and heart failure have stiffer arteries and reduced sensitivity to vasodilators compared with patients without hypertension, which can be reversed by sildenafil (Viagra), according to a study in the Aug. 11 issue of the Journal of the American College of Cardiology.

Vojtech Melenovsky, M.D., and colleagues from the Institute of Clinical and Experimental Medicine-IKEM in Prague, Czech Republic, examined 22 patients with heart failure and high pulmonary vascular resistance (H-PVR) and 24 matched patients with low pulmonary vascular resistance. Blood samples were taken to determine transpulmonary B-type natriuretic peptide (BNP) uptake and cyclic guanosine monophosphate (cGMP) release.

The researchers found that patients with H-PVR had normal BNP uptake, reduced cGMP release, lower pulmonary artery compliance, lower systemic arterial compliance, and a lower cardiac index. These could all be reversed after an oral dose of sildenafil, a phosphodiesterase-5A inhibitor.

"The H-PVR patients have stiffening of both pulmonary and systemic arteries, preserved transpulmonary BNP uptake, but diminished cGMP release, which is reversible by the administration of sildenafil," Melenovsky and colleagues conclude. "This study provides in vivo evidence that phosphodiesterase 5A inhibition restores sensitivity of pulmonary vasculature to endogenous cGMP-dependent vasodilators."

One of the authors is an advisory board member for several biotechnology companies.

Abstract
Full Text (subscription or payment may be required)

Copyright © 2009 ScoutNews, LLC. All rights reserved.


Previous: Induced Hypothermia After Cardiac Arrest Is Cost-Effective Next: Omega-3s Show Benefit in Cardiovascular Conditions

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2013
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.